BrainStorm Cell Therapeutics Inc. Will Host a Conference Call to Update Shareholders on Recent Developments

BrainStorm Cell Therapeutics Inc. Will Host a Conference Call to Update Shareholders on Recent Developments

<0> BrainStorm Cell Therapeutics Inc. (OTC: BCLI)Adrian Harel, Ph.D., CEO+972-3-9236384 </0>

BrainStorm Cell Therapeutics Inc. (OTC:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that its senior management will hold a conference call on Wednesday, July 25, 2012 at 8:00 a.m. EDT in Hebrew and at 8:45 a.m. EDT in English.

Dr. Adrian Harel, Chief Executive Officer, Mr. Chaim Lebovits, President, Ms. Liat Sossover, Chief Financial Officer, and Prof. Daniel Offen, PhD, Chief Scientific Advisor, will discuss the results of the Company's recent interim safety report and other developments.

Callers may participate in the conference call by dialing:

: 1-888-407-2553: 1-800-227-297 (Hebrew at 08:00 a.m. EDT), or 1-800-270-345 (English at 08:45 a.m. EDT).: +972-3-918-0664

Callers are invited to ask relevant questions during the conference call. Questions may also be pre-submitted to prior to 7:00 a.m. EDT on Wednesday, July 25, 2012.

A recording of the conference will be available for download Monday, July 30, 2012 from the company's website at the following link: .

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel-Aviv University. For more information, visit the company's website at .

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.